Wuhan YZY Biopharma Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was CNY 86.57 million compared to CNY 89.63 million a year ago. Basic loss per share from continuing operations was CNY 0.48 compared to CNY 0.53 a year ago.